Study on Ivonescimab for Treating Leiomyosarcoma

Inclusion Criteria

• Must be 18 years or older.
• Have a confirmed diagnosis of advanced or inoperable leiomyosarcoma.
• Willing to provide written consent and follow the study protocol.
• Have a performance status score of 0 to 2, indicating good overall health.
• Have received 1 to 3 previous treatments for leiomyosarcoma, or declined standard first-line treatment.
• Completed any prior radiation therapy at least 2 weeks before starting the study drug.
• Completed any prior chemotherapy or investigational treatments at least 3 weeks before starting the study drug.
• Have enough tumor tissue available for research purposes.
• Have measurable disease according to specific criteria.
• Have adequate organ function, including blood, kidney, and liver function.
• Women of childbearing age must have a negative pregnancy test and agree to use effective contraception during and after the study.
• Men must agree to use barrier contraception during and after the study.

Exclusion Criteria

• Previous treatment with certain immune or cancer-targeting drugs.
• History of autoimmune diseases requiring treatment in the past 2 years.
• Significant immune system suppression or infections.
• Recent major surgery or trauma.
• History of bleeding disorders or significant bleeding events.
• Poorly controlled high blood pressure.
• Active autoimmune or lung diseases requiring treatment.
• History of major heart or vascular diseases.
• Recent severe lung disease or gastrointestinal issues.
• Evidence of major blood vessel or organ invasion by the tumor.
• Active brain metastases or recent brain radiation.
• Recent live vaccinations.
• Severe infections or uncontrolled medical conditions.
• History of severe allergic reactions to study drugs.
• Pregnant or breastfeeding women.